The history of how we treat depression is the history of medicine, psychology, and culture arguing with each other over what depression actually is. This timeline traces depression treatment from the dawn of the modern pharmaceutical era in 1960 through the emerging ecosystem of 2027, covering the arrival of tricyclic antidepressants, the SSRI revolution of the late 1980s, the cognitive therapy evidence base, the integration of mindfulness and trauma-informed care, the ketamine and psychedelic renaissance, and the careful integration of digital and AI-assisted tools. The article names specific drugs, therapies, researchers, and institutional milestones, giving readers a clear picture of how depression care has changed in 67 years. Key figures include Dr. Aaron Beck, Dr. David Healy, Dr. Marsha Linehan, Dr. Bessel van der Kolk, Dr. Robert Waldinger, Dr. John Krystal, and Dr. Julianne Holt-Lunstad, whose research across pharmacology, psychotherapy, and social connection has shaped the modern understanding that depression is rarely best treated with a single approach.

What Are the Key Milestones?

Below are the pivotal moments in the history of how we treat depression, each representing a shift in theory, technology, or access.

1960: What Changed?

Imipramine, the first tricyclic antidepressant, became widely available for clinical use after its antidepressant effects were discovered by Swiss psychiatrist Dr. Roland Kuhn in 1957. For the first time in history, a pharmaceutical treatment existed that could directly target depressive symptoms. The era of biological psychiatry had begun.

1961: What Changed?

Dr. Aaron Beck published his influential paper on the "cognitive triad" of depression, describing how depressed patients held negative views of themselves, the world, and the future. This insight laid the foundation for Cognitive Behavioral Therapy (CBT) and began the slow shift away from purely psychodynamic approaches to depression.

1965: What Changed?

Dr. Joseph Schildkraut published the catecholamine hypothesis of depression in the American Journal of Psychiatry, proposing that depression was caused by a deficiency of norepinephrine in the brain. This was the birth of the "chemical imbalance" model, which would dominate public understanding of depression for the next 50 years despite being significantly more complicated than the simple model suggested.

1979: What Changed?

Dr. Aaron Beck published Cognitive Therapy of Depression, the foundational manual for cognitive therapy. This book laid out the specific techniques that would become CBT and provided the first major alternative to pharmaceutical treatment that had rigorous empirical support.

1987: What Changed?

The FDA approved fluoxetine (Prozac), the first Selective Serotonin Reuptake Inhibitor (SSRI). Prozac rapidly became a cultural phenomenon, making antidepressant treatment more accessible and acceptable to millions of people. By 1990, Prozac was on the cover of Newsweek and had reshaped public discourse about mental illness.

1993: What Changed?

Dr. Marsha Linehan published her foundational work on Dialectical Behavior Therapy (DBT), which, while originally designed for borderline personality disorder, proved effective for chronic suicidality and depression with complex presentations. DBT introduced mindfulness, distress tolerance, and emotion regulation skills into mainstream depression treatment.

2000: What Changed?

Dr. John Krystal and colleagues at Yale published the first research showing that ketamine, a dissociative anesthetic, produced rapid antidepressant effects in treatment-resistant depression. Though it would take another two decades for ketamine to become a mainstream treatment, this paper was the beginning of the rapid-acting antidepressant revolution.

2002: What Changed?

Dr. Zindel Segal, Dr. Mark Williams, and Dr. John Teasdale published Mindfulness-Based Cognitive Therapy for Depression, introducing MBCT as a relapse prevention tool for recurrent depression. Research showed MBCT reduced relapse rates by nearly 50 percent in patients with three or more prior episodes.

2004: What Changed?

The FDA issued a black box warning on antidepressants for increased suicidal ideation in adolescents, prompting a cultural reckoning with the limitations of the SSRI model. Dr. David Healy and others critiqued the industry marketing of antidepressants and called for more rigorous evaluation of long-term outcomes.

2008: What Changed?

A meta-analysis by Dr. Irving Kirsch in PLOS Medicine argued that SSRIs offered only modest benefits over placebo for mild to moderate depression, reigniting debate about the place of medication in treatment. The paper contributed to a more nuanced public understanding of when and for whom antidepressants were most effective.

2010: What Changed?

Dr. Julianne Holt-Lunstad published her meta-analysis showing that social connection was a stronger predictor of mortality than diet, exercise, or BMI. Though not a depression study per se, this research began the slow integration of social connection as a core part of depression treatment, not just a peripheral support.

2013: What Changed?

The American Psychiatric Association released DSM-5, which controversially removed the bereavement exclusion for major depressive disorder. Critics argued this pathologized normal grief, while supporters argued it ensured grieving people could access treatment.

2014: What Changed?

Dr. Bessel van der Kolk published The Body Keeps the Score, bringing trauma-informed care into mainstream clinical practice. The book argued that many cases of treatment-resistant depression were actually unprocessed trauma, and that somatic and experiential therapies should be considered alongside medication and CBT.

2015: What Changed?

The Johns Hopkins and NYU psilocybin research programs published groundbreaking studies showing that a single guided psilocybin session produced meaningful and sustained reductions in depression and anxiety in patients with terminal illness. This reopened a field that had been dormant since the 1970s.

2019: What Changed?

The FDA approved esketamine (Spravato) nasal spray for treatment-resistant depression, becoming the first new mechanism of antidepressant action approved in decades. This marked the official arrival of rapid-acting antidepressants in mainstream practice.

2020: What Changed?

The COVID-19 pandemic produced the largest single-year increase in depression rates ever recorded, with rates nearly tripling in young adults by some measures. Treatment access became a crisis, accelerating the shift to tele-therapy and digital mental health tools.

2022: What Changed?

Psilocybin assisted therapy research led by Dr. Robin Carhart-Harris and others showed comparable outcomes to SSRIs in treating depression, with a single guided session producing sustained effects. Multiple state-level initiatives began to legalize supervised psilocybin therapy, with Oregon leading the way.

2023: What Changed?

U.S. Surgeon General Dr. Vivek Murthy issued the loneliness advisory, and research integrating Dr. Julianne Holt-Lunstad and Dr. Robert Waldinger findings made social connection a formally recommended component of depression treatment for the first time. The recognition that depression is partly a relational condition reshaped treatment planning.

2024: What Changed?

Randomized controlled trials of large-language-model therapy chatbots like the Dartmouth Therabot study showed meaningful symptom reduction in depression and anxiety. These tools were positioned as adjunctive rather than primary care, but they opened new access pathways for people who could not afford or access traditional therapy.

2025: What Changed?

Dr. Kristin Neff research on self-compassion as a depression intervention reached the mainstream, with large-scale randomized trials showing meaningful reductions in depressive symptoms through self-compassion practices. Self-compassion joined mindfulness, CBT, and medication as an evidence-based treatment component.

2026: What Changed?

Voice-enabled AI companions capable of conversational support became widely available, with research suggesting they could reduce loneliness and provide between-session support for people in treatment. The field emphasized AI as a bridge, not a replacement, for human care.

2027: What Changed?

The current consensus is that depression is best treated with a combination approach tailored to the individual, medication when indicated, evidence-based psychotherapy (CBT, DBT, MBCT, EFT, or trauma-focused care), attention to social connection and loneliness, lifestyle factors, and, for some, AI-assisted support tools that help bridge the gaps between human sessions. The era of "one treatment fits all" is definitively over. The history of depression treatment is a story of expanding options and deepening humility. From the first tricyclic in 1960 to the integration of AI companions in 2027, each era has added tools rather than replacing the old ones. Dr. Robert Waldinger Harvard research is now widely cited in depression care, warm, reciprocal relationships are the single most protective factor against depression across the lifespan. The best depression treatment of 2027 includes medicine, therapy, and the harder, slower work of rebuilding the connections that make life feel worth living.